SSGJ 613
Alternative Names: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection - Sunshine Guojian Pharmaceutical; SSGJ-613; SSGJ-613 100mgLatest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Sunshine Guojian Pharmaceutical
- Class Antigouts; Antipyretics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gouty arthritis
- Phase I/II Gout
- No development reported Fever; Juvenile rheumatoid arthritis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Fever(In volunteers, In adults) in China (SC, Injection)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Juvenile-rheumatoid-arthritis(In volunteers, In adults) in China (SC, Injection)
- 12 Jun 2024 Efficacy and adverse events data from a phase Ib/II trial in Gout presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)